Medtronic acquires license to DreaMed Diabetes' artificial pancreas technology

“We are certain that this partnership will improve the health as well as the quality of life of people living with diabetes.”

DreaMed Diabetes and Medtronic announced an exclusive worldwide development and license agreement for products that will incorporate DreaMed’s MD-Logic Artificial Pancreas algorithm into Medtronic’s integrated insulin pump and glucose monitoring systems. A research team led by Moshe Phillip, MD, Chairman and Chief Scientific Officer of DreaMed Diabetes, and Director of the Institute for Endocrinology and Diabetes, Schneider Children’s Medical Center of Israel, developed GlucoSitter™, a fully automated artificial pancreas system based on the company’s proprietary algorithm. As part of the agreement, Medtronic invested $2 million in DreaMed, which will receive royalties on sales of devices using MD-Logic. 


Updates from the Field
Google receives patent for glucose-sensing contact lens
The U.S. Patent & Trademark Office approved Google’s patent application (filed September 2012) for a “contact lens having an uneven embedded substrate and method of manufacture”—a lens that incorporates a sensor and a chip linked by an interconnected circuit. In mid-2014 Google and Novartis, through its Alcon eye care division, announced a partnership to develop a smart contact lens capable of measuring blood sugar levels using tear fluid and uploading the data to a mobile device. 

Diabetes Technology & Therapeutic


www red DiabetologNytt